Back to News
Market Impact: 0.2
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesTransportation & Logistics
An agreement establishes a dedicated U.S. commercial channel for REZENOPY across approximately 2,000 opioid treatment program clinics and other addiction-treatment center networks. The expanded distribution access could improve product availability in a targeted healthcare market, though the article provides no financial terms, revenue forecast, or sales commitments.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Why a wave of bomb threats is proving so difficult for Europe's aviation authorities to contain
- Russia to UAE, Iran steps up diplomacy amid Trump threats: What we know
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Musk says Tesla to wind down polarising Cybertruck production as sales lag
- Soaring freight rates give US refiners edge as crude discounts widen
- Tesla to wind down Cybertruck production at Texas factory next year to make room for Cybercab